Drug intelligence / Profile preview

MED223

Development stage: Preclinical
Lead developer: Medley Therapeutics
Administration: Intravenous, Intramuscular

Overview

MED223 is an experimental advanced biologic candidate being developed by Medley Therapeutics (formerly YAP Therapeutics) for the treatment of idiopathic pulmonary fibrosis (IPF). It is a product of the company's Advanced Biologics Platform, which focuses on addressing fibrosis and solid tumor cancers. This platform is distinct from the company's Genetic Medicine Platform, which primarily targets the YAP/Hippo pathway to activate regenerative capabilities in cardiac and vascular tissues. As of early 2024, MED223 is in the discovery stage of development, and its specific molecular target and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on MED223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MED223.

Explore the full profile